Diagnostic accuracy of cancer ratio and other new parameters in differentiating malignant from benign pleural effusions

Submitted: July 11, 2024
Accepted: October 4, 2024
Published: December 6, 2024
Abstract Views: 96
PDF_EARLY VIEW: 22
SUPPLEMENTARY MATERIAL: 3
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Differentiation of malignant from benign pleural effusions is challenging in clinical practice due to limitations in the cytologic analysis. The combination of pleural fluid biomarkers has previously been used to predict malignant pleural effusion (MPE). We have conducted a prospective observational study to assess the diagnostic potential of cancer ratio [(CR) serum lactate dehydrogenase (sLDH): pleural fluid adenosine deaminase (pADA)], CR plus (CR: pleural lymphocyte count), sLDH: pleural lymphocyte count, and age: pADA in differentiating malignant effusions from benign ones. Prospective data from patients evaluated for exudative pleural effusions in the pulmonary medicine department at our institute over 12 months were collected. All subjects underwent thoracentesis, and if the results were inconclusive, they underwent invasive diagnostic testing for confirmation. They were divided into MPE and non-MPE groups for analysis. Pleural fluid biomarker ratios were calculated and compared between both groups, and receiver operating characteristic curves were generated. We included 120 subjects: 59 were diagnosed with MPE, and 61 had benign effusion (46 tubercular and 15 parapneumonic). The mean (standard deviation) age of the study population [64 (53.3%) males] was 52.4 (14.5) years. CR, CR plus, and age: pADA were significantly higher in the MPE group compared to the benign group. The sLDH: lymphocyte count was similar between both groups. Age: pADA ratio and CR performed best, with areas under the curve of 0.99 [95% confidence interval (CI), 0.97-1.0] and 0.97 (95% CI, 0.94-1.0) respectively. A higher age: pADA level was associated with a malignant etiology of effusion (adjusted odds ratio 12.27, 95% CI 2.37-63.54) on multivariate analysis. At a cut-off of 2, age: pADA ratio provided 96.6% sensitivity, 93.4% specificity, with a positive likelihood ratio of 14.7. Age: pADA and CR are promising diagnostic indices for differentiating MPE and non-MPE with high sensitivity and specificity. The diagnostic accuracy of CR plus and sLDH: lymphocyte ratio is inferior to that of CR and age: pADA.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Shen-Wagner J, Gamble C, MacGilvray P. Pleural effusion: diagnostic approach in adults. Am Fam Physician 2023;108:464-75.
Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002;346:1971-7. DOI: https://doi.org/10.1056/NEJMcp010731
Loddenkemper R, Mathur PN, Lee P, Noppen M. History and clinical use of thoracoscopy/pleuroscopy in respiratory medicine. Breathe 2011;8:144-55. DOI: https://doi.org/10.1183/20734735.011711
Lo Cascio CM, Kaul V, Dhooria S, et al. Diagnosis of tuberculous pleural effusions: a review. Respir Med 2021;188:106607. DOI: https://doi.org/10.1016/j.rmed.2021.106607
Kassirian S, Hinton SN, Cuninghame S, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax 2023;78:32-40. DOI: https://doi.org/10.1136/thoraxjnl-2021-217959
Kumar R. Empirical use of antituberculosis drugs should not be equated to their inappropriate and indiscriminate use. Indian J Pharmacol 2011;43:363-4. DOI: https://doi.org/10.4103/0253-7613.81494
Zhang M, Yan L, Lippi G, Hu ZD. Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Transl Lung Cancer Res 2021;10:1557-70. DOI: https://doi.org/10.21037/tlcr-20-1111
Verma A, Abisheganaden J, Light RW. Identifying malignant pleural effusion by a cancer ratio (serum LDH: pleural fluid ADA ratio). Lung 2016;194:147-53. DOI: https://doi.org/10.1007/s00408-015-9831-6
Verma A, Dagaonkar RS, Marshall D, et al. Differentiating malignant from tubercular pleural effusion by cancer ratio plus (cancer ratio: pleural lymphocyte count). Can Respir J 2016;2016:7348239. DOI: https://doi.org/10.1155/2016/7348239
Korczynski P, Mierzejewski M, Krenke R, et al. Differentiation between malignant and non-malignant pleural effusion using cancer ratio and other new parameters. Pol Arch Intern Med 2018;128:354-61. DOI: https://doi.org/10.20452/pamw.4278
ElSharawy DE, Hagras MM, Khedr RA. The clinical utility of joined detection of cancer ratio, cancer ratio plus, Interferon gamma (IFN-ϒ) & Carcinoembryonic antigen (CEA) in differentiating lymphocytic pleural effusions. Egypt J Bronchol 2020;14:3. DOI: https://doi.org/10.1186/s43168-020-00003-4
Feng Y, Xiong Y, Qiao T, et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med 2018;7:6124-36. DOI: https://doi.org/10.1002/cam4.1820
Gayaf M, Anar C, Canbaz M, et al. Value of cancer ratio plus and cancer ratio formulation in distinguishing malignant pleural effusion from tuberculosis and parapneumonic effusion. Tanaffos 2021;20:221-31.
Zhou J, Yang Y, Zhang Y, et al. Age : pleural fluid ADA ratio and other indicators for differentiating between tubercular and malignant pleural effusions. Medicine 2022;101:e29788. DOI: https://doi.org/10.1097/MD.0000000000029788
Huang JH, Chen H, Zhang ZC, et al. Age affects the diagnostic accuracy of the cancer ratio for malignant pleural effusion. BMC Pulm Med 2023;23:198. DOI: https://doi.org/10.1186/s12890-023-02475-8
Gui X, Xiao H. Diagnosis of tuberculosis pleurisy with adenosine deaminase (ADA): a systematic review and meta-analysis. Int J Clin Exp Med 2014;7:3126-35.
Zhang F, Hu L, Wang J, et al. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. J Clin Lab Anal 2017;31:e22106. DOI: https://doi.org/10.1002/jcla.22106
Zhang Y, Li X, Liu J, et al. Diagnostic accuracy of the cancer ratio for the prediction of malignant pleural effusion: evidence from a validation study and meta-analysis. Ann Med 2021;53:558-66. DOI: https://doi.org/10.1080/07853890.2021.1906943
Hussein SA, Elhefnawy MY. Relations between serum and pleural fluid biomarkers: a new look of an old concept. Egypt J Bronchol 2020;14:4. DOI: https://doi.org/10.1186/s43168-020-00004-3
Ren Z, Xu L. Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion. Clinics 2021;76:e2515. DOI: https://doi.org/10.6061/clinics/2021/e2515

Ethics Approval

Institute ethical committee clearance obtained (EC/NIMS/3025/2022).

How to Cite

Narahari, Narendra Kumar, Nandini Ravula, Rakesh Kodati, Shantveer G Uppin, Saibaba KSS, Bhaskar Kakarla, and Paramjyothi Gongati. 2024. “Diagnostic Accuracy of Cancer Ratio and Other New Parameters in Differentiating Malignant from Benign Pleural Effusions”. Monaldi Archives for Chest Disease, December. https://doi.org/10.4081/monaldi.2024.3131.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.